Advertisement
RARE vs ZYME
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RARE is a Buy and ZYME is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RARE’s FA Score shows that 0 FA rating(s) are green whileZYME’s FA Score has 0 green FA rating(s).
- RARE’s FA Score: 0 green, 5 red.
- ZYME’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RARE’s TA Score shows that 3 TA indicator(s) are bullish while ZYME’s TA Score has 4 bullish TA indicator(s).
- RARE’s TA Score: 3 bullish, 6 bearish.
- ZYME’s TA Score: 4 bullish, 4 bearish.
Price Growth
RARE (@Biotechnology) experienced а -1.67% price change this week, while ZYME (@Biotechnology) price change was -0.08% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.
Reported Earning Dates
RARE is expected to report earnings on Jul 31, 2025.
Industries' Descriptions
@Biotechnology (+4.13% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| RARE | ZYME | RARE / ZYME | |
| Capitalization | 3.45B | 868M | 398% |
| EBITDA | -449.9M | -110.05M | 409% |
| Gain YTD | -13.192 | -14.822 | 89% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 591M | 93.4M | 633% |
| Total Cash | 494M | 265M | 186% |
| Total Debt | 38.3M | 18.5M | 207% |
RARE | ZYME | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 68 | 79 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | 44 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 95 | |
PRICE GROWTH RATING 1..100 | 59 | 48 | |
P/E GROWTH RATING 1..100 | 100 | 66 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ZYME's Valuation (44) in the Pharmaceuticals Major industry is somewhat better than the same rating for RARE (79) in the Biotechnology industry. This means that ZYME’s stock grew somewhat faster than RARE’s over the last 12 months.
ZYME's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as RARE (100) in the Biotechnology industry. This means that ZYME’s stock grew similarly to RARE’s over the last 12 months.
ZYME's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as RARE (100) in the Biotechnology industry. This means that ZYME’s stock grew similarly to RARE’s over the last 12 months.
ZYME's Price Growth Rating (48) in the Pharmaceuticals Major industry is in the same range as RARE (59) in the Biotechnology industry. This means that ZYME’s stock grew similarly to RARE’s over the last 12 months.
ZYME's P/E Growth Rating (66) in the Pharmaceuticals Major industry is somewhat better than the same rating for RARE (100) in the Biotechnology industry. This means that ZYME’s stock grew somewhat faster than RARE’s over the last 12 months.
| RARE | ZYME | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 77% | N/A |
| Stochastic ODDS (%) | 2 days ago 73% | 2 days ago 77% |
| Momentum ODDS (%) | 2 days ago 76% | 2 days ago 79% |
| MACD ODDS (%) | 2 days ago 75% | 2 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 79% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 72% | 2 days ago 80% |
| Advances ODDS (%) | N/A | N/A |
| Declines ODDS (%) | 12 days ago 80% | 12 days ago 83% |
| BollingerBands ODDS (%) | 2 days ago 89% | 2 days ago 73% |
| Aroon ODDS (%) | 2 days ago 71% | 2 days ago 81% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| RNNEX | 64.17 | 0.29 | +0.45% |
| American Funds New Economy R2E | |||
| APDQX | 15.36 | 0.06 | +0.39% |
| Artisan Mid Cap Value Advisor | |||
| PSVDX | 16.41 | 0.05 | +0.31% |
| PGIM Quant Solutions Small-Cap Val R2 | |||
| TSPRX | 5.56 | 0.01 | +0.18% |
| Transamerica Small Cap Growth R | |||
| JGSVX | 21.34 | 0.02 | +0.09% |
| JPMorgan Small Cap Growth R5 | |||
RARE and
Correlation & Price change
A.I.dvisor indicates that over the last year, RARE has been loosely correlated with CRNX. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if RARE jumps, then CRNX could also see price increases.
| Ticker / NAME | Correlation To RARE | 1D Price Change % | ||
|---|---|---|---|---|
| RARE | 100% | -2.43% | ||
| CRNX - RARE | 52% Loosely correlated | -1.48% | ||
| COGT - RARE | 51% Loosely correlated | -3.14% | ||
| DNLI - RARE | 50% Loosely correlated | -2.69% | ||
| RVMD - RARE | 50% Loosely correlated | -1.52% | ||
| NUVL - RARE | 49% Loosely correlated | +0.70% | ||
More | ||||
ZYME and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZYME has been loosely correlated with AGIO. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYME jumps, then AGIO could also see price increases.
| Ticker / NAME | Correlation To ZYME | 1D Price Change % | ||
|---|---|---|---|---|
| ZYME | 100% | +0.81% | ||
| AGIO - ZYME | 49% Loosely correlated | -0.53% | ||
| ABCL - ZYME | 47% Loosely correlated | -3.48% | ||
| ABEO - ZYME | 47% Loosely correlated | -2.54% | ||
| RARE - ZYME | 47% Loosely correlated | -2.43% | ||
| BEAM - ZYME | 46% Loosely correlated | -1.98% | ||
More | ||||